None listed
Conditions
Brief summary
Cerebral vasospasm influences morbidity and mortality following subarachnoid haemorrhage (SAH). Current therapeutic protocols do not show enough therapeutic effects in prevention and treatment of vasospasm. Inflammation is believed to play an important role in post-haemorrhagic vasospasm. Meloxicam is a non-steroidal anti-inflammatory drug. The aim of the study is investigation the comparative efficacy of meloxicam and plasebo on vasospasm in patients with SAH in Shariati Hospital. In this randomized, double-blind, placebo-controlled trial, SAH patients randomly received 7.5 mg meloxicam or placebo twice daiy for 7 days. End points were, middle cerebral artery (MCA) velocity obtained with transcranial doppler, length of hospital stay and discharge Glasgow Outcome Scale scores.
Interventions
In this randomized, double-blind, placebo-controlled trial, SAH patients randomly received 7.5 mg oral tablet meloxicam or placebo twice daily for 7 days. Since patients were hospitalized all of the medication administered by nurses.
Sponsors
Tehran University of Medical Sciences
Study design
Allocation
Randomised controlled trial
Primary purpose
Treatment
Eligibility
Sex/Gender
All
Age
0 to No maximum
Healthy volunteers
No
Inclusion criteria
Patients with diagnosis of subarachnoid hemorrhage documented by Computed Tomography (CT) scan who admitted to neurosurgery and neurology wards of Shariati hospital.
Exclusion criteria
Meloxicam contraindications: Meloxicam, aspirin, or any other NSAIDs sensitivity Serious adverse reaction induced by meloxicam Long term use of meloxicam or any other NSAIDs before the study Occurrence of rebleeding in patient leading to emergency neurosurgical operation Serious interaction between patient's medications and meloxicam Unstable hemodynamic condition in patient making doppler sonography impossible
Outcome results
None listed